Abstract
Urinary tract infection (UTI) is among the most common infectious diseases of humans and is the most common nosocomial infection in the developed world. They cause significant morbidity and mortality, with approximately 150 million cases globally per year. It is estimated that 40-50% of women and 5% of men will develop a UTI in their lifetime, and UTI accounts for more than 1 million hospitalizations and $1.6 billion in medical expenses each year in the USA. Uropathogenic E. coli (UPEC) is the primary cause of UTI. This review presents an overview of the primary virulence factors of UPEC, the major host responses to infection of the urinary tract, the emergence of specific multidrug resistant clones of UPEC, antibiotic treatment options for UPEC-mediated UTI and the current state of vaccine strategies as well as other novel anti-adhesive and prophylactic approaches to prevent UTI. New and emerging themes in UPEC research are also discussed in the context of future outlooks.
Keywords: Antibiotic resistance, uropathogenic Escherichia coli, vaccine, virulence, Urinary Tract Infection, UPEC, UTI, bladder infection (cystitis), acute kidney infection (pyelonephritis), pathogens.
Current Drug Targets
Title:Uropathogenic Escherichia coli Mediated Urinary Tract Infection
Volume: 13 Issue: 11
Author(s): Makrina Totsika, Danilo Gomes Moriel, Adi Idris, Benjamin A. Rogers, Daniel J. Wurpel, Minh-Duy Phan, David L. Paterson and Mark A. Schembri
Affiliation:
Keywords: Antibiotic resistance, uropathogenic Escherichia coli, vaccine, virulence, Urinary Tract Infection, UPEC, UTI, bladder infection (cystitis), acute kidney infection (pyelonephritis), pathogens.
Abstract: Urinary tract infection (UTI) is among the most common infectious diseases of humans and is the most common nosocomial infection in the developed world. They cause significant morbidity and mortality, with approximately 150 million cases globally per year. It is estimated that 40-50% of women and 5% of men will develop a UTI in their lifetime, and UTI accounts for more than 1 million hospitalizations and $1.6 billion in medical expenses each year in the USA. Uropathogenic E. coli (UPEC) is the primary cause of UTI. This review presents an overview of the primary virulence factors of UPEC, the major host responses to infection of the urinary tract, the emergence of specific multidrug resistant clones of UPEC, antibiotic treatment options for UPEC-mediated UTI and the current state of vaccine strategies as well as other novel anti-adhesive and prophylactic approaches to prevent UTI. New and emerging themes in UPEC research are also discussed in the context of future outlooks.
Export Options
About this article
Cite this article as:
Totsika Makrina, Gomes Moriel Danilo, Idris Adi, A. Rogers Benjamin, J. Wurpel Daniel, Phan Minh-Duy, L. Paterson David and A. Schembri Mark, Uropathogenic Escherichia coli Mediated Urinary Tract Infection, Current Drug Targets 2012; 13 (11) . https://dx.doi.org/10.2174/138945012803530206
DOI https://dx.doi.org/10.2174/138945012803530206 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Furanodienone: An Emerging Bioactive Furanosesquiterpenoid
Current Organic Chemistry Atranorin – An Interesting Lichen Secondary Metabolite
Mini-Reviews in Medicinal Chemistry Redox State, Oxidative Stress, and Molecular Mechanisms of Protective and Toxic Effects of Bilirubin on Cells
Current Pharmaceutical Design Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Mechanisms of the Resistance and Tolerance to Beta-Lactam and Glycopeptide Antibiotics in Pathogenic Gram-Positive Cocci
Mini-Reviews in Medicinal Chemistry Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design Amyloid β Accumulation Assessed with <sup>11</sup>C-Pittsburgh Compound B PET and Postmortem Neuropathology
Current Alzheimer Research Early Detection of Central Nervous System Relapse of Pediatric Leukemia with Measurement of Optic Nerve Sheath Diameter on MRI
Current Medical Imaging Advances in TB Vaccinology
Current Respiratory Medicine Reviews The Quantitative Structure Activity Relationships for Predicting HIV Protease Inhibition by Substituted Fullerenes
Letters in Drug Design & Discovery Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Colored Representation of Brain Gray Scale MRI Images to Potentially Underscore the Variability and Sensitivity of Images
Current Medical Imaging Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Antiepileptic Drug-Induced Hypersensitivity Syndrome Reactions
Current Drug Safety In Vivo Cellular Imaging for Translational Medical Research
Current Medical Imaging Listeria-Based Anti-Infective Vaccine Strategies
Recent Patents on Anti-Infective Drug Discovery Recent Advances on Neural Tube Defects with Special Reference to Valproic Acid
Endocrine, Metabolic & Immune Disorders - Drug Targets Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease
Current Medicinal Chemistry Multiple Roles of the Extracellular Matrix in Inflammation
Current Pharmaceutical Design Prolactin Protects Against the Methamphetamine-Induced Cerebral Vascular Toxicity
Current Neurovascular Research